Baidu
map

Int J Clin Pract:幽门螺杆菌:14天高剂量埃索美拉唑+阿莫西林+甲硝唑是否有效?

2017-10-23 常路 环球医学

目前推荐的治疗幽门螺杆菌的三线疗法疗效不佳。2017年9月,发表在《Int J Clin Pract.》的一项研究调查了14天使用高剂量埃索美拉唑、阿莫西林和甲硝唑作为幽门螺杆菌三线治疗的有效性和安全性。

目前推荐的治疗幽门螺杆菌的三线疗法疗效不佳。2017年9月,发表在《Int J Clin Pract.》的一项研究调查了14天使用高剂量埃索美拉唑、阿莫西林和甲硝唑作为幽门螺杆菌三线治疗的有效性和安全性。

简介:目前推荐的治疗幽门螺杆菌的三线疗法疗效不佳,甚至是在细胞培养结果指导的治疗中也不能产生效果。该研究的目的是评价使用14天高剂量阿莫西林、甲硝唑和埃索美拉唑疗法的有效性和安全性。

材料和方法:在有2次既往根除治疗失败史的患者中开展一项多中心、开放标签研究,作为临床实践的一个日常注册。在首次治疗使用包含克拉霉素,第二次治疗使用包括喹诺酮在内的药物后,采用埃索美拉唑4 0 mg每日1次、阿莫西林1 g每日3次和甲硝唑500 mg每日3次,进行为期2周的三联疗法,作为幽门螺杆菌的三线疗法。通过治疗前后组织学或13C-UBT结果,确定幽门螺杆菌的状态。

结果:本研究共纳入68例患者。中期分析显示,在既往根除方案中使用甲硝唑的8例患者中有3例治愈(37%,95%CI 8~75);因此在该中期分析后仅纳入没有使用甲硝唑的患者。既往没有使用甲硝唑的患者中ITT根除率为64%(95%CI 51~76)。58%的患者发生不良事件,均为轻度至中度。2例患者(3%)由于不良事件没有完成>90%的治疗。没有严重不良事件发生。

结论:14天使用高剂量埃索美拉唑、阿莫西林和甲硝唑作为三线根除方案的治愈率欠佳,尤其是在既往根除方案已经包括甲硝唑的患者中。

原始出处:

Puig I, González-Santiago JM, Molina-Infante J, et al. Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for Helicobacter pylori infection. Int J Clin Pract. 2017 Sep;71(9). doi: 10.1111/ijcp.13004. Epub 2017 Sep 4.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=337370, encodeId=6e7233e37027, content=谢谢,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Wed Aug 08 21:58:40 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811733, encodeId=79c01811e334c, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Apr 24 21:56:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942075, encodeId=58d119420e5cc, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Feb 07 08:56:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299285, encodeId=0dc1129928515, content=<a href='/topic/show?id=5413699307e' target=_blank style='color:#2F92EE;'>#甲硝唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69930, encryptionId=5413699307e, topicName=甲硝唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3860283, createdName=whmdzju, createdTime=Wed Oct 25 07:56:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591746, encodeId=15c21591e469f, content=<a href='/topic/show?id=90cb415e5f2' target=_blank style='color:#2F92EE;'>#埃索美拉唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41575, encryptionId=90cb415e5f2, topicName=埃索美拉唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Wed Oct 25 07:56:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255551, encodeId=495225555175, content=学习学习.了解较劲, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Oct 24 08:00:45 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255363, encodeId=f7d7255363df, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Oct 23 18:41:50 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2018-08-08 cscdliu

    谢谢,学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=337370, encodeId=6e7233e37027, content=谢谢,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Wed Aug 08 21:58:40 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811733, encodeId=79c01811e334c, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Apr 24 21:56:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942075, encodeId=58d119420e5cc, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Feb 07 08:56:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299285, encodeId=0dc1129928515, content=<a href='/topic/show?id=5413699307e' target=_blank style='color:#2F92EE;'>#甲硝唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69930, encryptionId=5413699307e, topicName=甲硝唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3860283, createdName=whmdzju, createdTime=Wed Oct 25 07:56:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591746, encodeId=15c21591e469f, content=<a href='/topic/show?id=90cb415e5f2' target=_blank style='color:#2F92EE;'>#埃索美拉唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41575, encryptionId=90cb415e5f2, topicName=埃索美拉唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Wed Oct 25 07:56:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255551, encodeId=495225555175, content=学习学习.了解较劲, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Oct 24 08:00:45 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255363, encodeId=f7d7255363df, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Oct 23 18:41:50 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2018-04-24 kcb069
  3. [GetPortalCommentsPageByObjectIdResponse(id=337370, encodeId=6e7233e37027, content=谢谢,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Wed Aug 08 21:58:40 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811733, encodeId=79c01811e334c, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Apr 24 21:56:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942075, encodeId=58d119420e5cc, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Feb 07 08:56:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299285, encodeId=0dc1129928515, content=<a href='/topic/show?id=5413699307e' target=_blank style='color:#2F92EE;'>#甲硝唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69930, encryptionId=5413699307e, topicName=甲硝唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3860283, createdName=whmdzju, createdTime=Wed Oct 25 07:56:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591746, encodeId=15c21591e469f, content=<a href='/topic/show?id=90cb415e5f2' target=_blank style='color:#2F92EE;'>#埃索美拉唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41575, encryptionId=90cb415e5f2, topicName=埃索美拉唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Wed Oct 25 07:56:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255551, encodeId=495225555175, content=学习学习.了解较劲, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Oct 24 08:00:45 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255363, encodeId=f7d7255363df, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Oct 23 18:41:50 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2018-02-07 amy0550
  4. [GetPortalCommentsPageByObjectIdResponse(id=337370, encodeId=6e7233e37027, content=谢谢,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Wed Aug 08 21:58:40 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811733, encodeId=79c01811e334c, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Apr 24 21:56:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942075, encodeId=58d119420e5cc, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Feb 07 08:56:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299285, encodeId=0dc1129928515, content=<a href='/topic/show?id=5413699307e' target=_blank style='color:#2F92EE;'>#甲硝唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69930, encryptionId=5413699307e, topicName=甲硝唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3860283, createdName=whmdzju, createdTime=Wed Oct 25 07:56:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591746, encodeId=15c21591e469f, content=<a href='/topic/show?id=90cb415e5f2' target=_blank style='color:#2F92EE;'>#埃索美拉唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41575, encryptionId=90cb415e5f2, topicName=埃索美拉唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Wed Oct 25 07:56:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255551, encodeId=495225555175, content=学习学习.了解较劲, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Oct 24 08:00:45 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255363, encodeId=f7d7255363df, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Oct 23 18:41:50 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2017-10-25 whmdzju
  5. [GetPortalCommentsPageByObjectIdResponse(id=337370, encodeId=6e7233e37027, content=谢谢,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Wed Aug 08 21:58:40 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811733, encodeId=79c01811e334c, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Apr 24 21:56:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942075, encodeId=58d119420e5cc, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Feb 07 08:56:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299285, encodeId=0dc1129928515, content=<a href='/topic/show?id=5413699307e' target=_blank style='color:#2F92EE;'>#甲硝唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69930, encryptionId=5413699307e, topicName=甲硝唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3860283, createdName=whmdzju, createdTime=Wed Oct 25 07:56:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591746, encodeId=15c21591e469f, content=<a href='/topic/show?id=90cb415e5f2' target=_blank style='color:#2F92EE;'>#埃索美拉唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41575, encryptionId=90cb415e5f2, topicName=埃索美拉唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Wed Oct 25 07:56:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255551, encodeId=495225555175, content=学习学习.了解较劲, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Oct 24 08:00:45 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255363, encodeId=f7d7255363df, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Oct 23 18:41:50 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=337370, encodeId=6e7233e37027, content=谢谢,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Wed Aug 08 21:58:40 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811733, encodeId=79c01811e334c, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Apr 24 21:56:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942075, encodeId=58d119420e5cc, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Feb 07 08:56:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299285, encodeId=0dc1129928515, content=<a href='/topic/show?id=5413699307e' target=_blank style='color:#2F92EE;'>#甲硝唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69930, encryptionId=5413699307e, topicName=甲硝唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3860283, createdName=whmdzju, createdTime=Wed Oct 25 07:56:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591746, encodeId=15c21591e469f, content=<a href='/topic/show?id=90cb415e5f2' target=_blank style='color:#2F92EE;'>#埃索美拉唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41575, encryptionId=90cb415e5f2, topicName=埃索美拉唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Wed Oct 25 07:56:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255551, encodeId=495225555175, content=学习学习.了解较劲, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Oct 24 08:00:45 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255363, encodeId=f7d7255363df, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Oct 23 18:41:50 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2017-10-24 1dd8c52fm63(暂无匿称)

    学习学习.了解较劲

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=337370, encodeId=6e7233e37027, content=谢谢,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Wed Aug 08 21:58:40 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811733, encodeId=79c01811e334c, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Apr 24 21:56:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942075, encodeId=58d119420e5cc, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Feb 07 08:56:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299285, encodeId=0dc1129928515, content=<a href='/topic/show?id=5413699307e' target=_blank style='color:#2F92EE;'>#甲硝唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69930, encryptionId=5413699307e, topicName=甲硝唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3860283, createdName=whmdzju, createdTime=Wed Oct 25 07:56:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591746, encodeId=15c21591e469f, content=<a href='/topic/show?id=90cb415e5f2' target=_blank style='color:#2F92EE;'>#埃索美拉唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41575, encryptionId=90cb415e5f2, topicName=埃索美拉唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Wed Oct 25 07:56:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255551, encodeId=495225555175, content=学习学习.了解较劲, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Oct 24 08:00:45 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255363, encodeId=f7d7255363df, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Oct 23 18:41:50 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2017-10-23 131****1460

    学习了受益匪浅

    0

相关资讯

J Antimicr Chemoth:优化术前预防 SRBA患者的抗菌药物管理新延伸

2017年9月,发表在《J Antimicrob Chemother》的一项由加拿大科学家进行的研究,考察了自我报告的β-内酰胺类药物过敏(SRBA)患者中,优化术前二线抗菌药管理对减少不良反应的效果。

为何宝宝总是眼泪汪汪?一分钟教会你止“哭”要领

急性泪囊炎是一种泪囊及其周围组织的急性化脓性炎症。由于鼻泪管被堵塞,泪囊里面的泪液不能排出,以致潴留的泪液成了细菌生长、繁殖的场所,长期反复感染容易形成慢性泪囊炎。而有些慢性泪囊炎可向周围扩散,造成急性发作。

感染映像:肺里有个会滚的球,咋回事呢?

一位男性患者,苏丹人,25岁,因咳嗽及痰中带血1月就诊。6年前他曾有相似的症状发作,持续约5周,期间还伴有夜间盗汗、体重减轻、乏力等症状。当时他接受了经验性抗结核治疗。而在此次就诊的病史陈述中,患者无发热,血氧饱和度正常,肺部听诊呼吸音正常,人类免疫缺陷病毒检测阴性。胸部X线检查提示左肺上叶有空洞,结核菌素皮内试验显示为12mm硬结。痰涂片和培养结果提示抗酸杆菌阴性。胸部CT显示两上肺空洞,左上肺

产后侧切感染 不要紧盯高锰酸钾

顺产时为了保证母亲和孩子的安全,经常需要做会阴侧切。由于会阴部容易受到恶露、尿液、粪便的污染,一部分宝妈会发生会阴部侧切伤口感染,造成局部肿胀、疼痛、无法行走,甚至坐卧不安。

Blood:靶向CD19的嵌合抗原受体修饰的T细胞免疫疗法的感染性并发症研究。

Lymphodepletion化疗联合CD19靶向嵌合抗原受体修饰的T(CAR-T)细胞是对难治性或复发性B细胞恶性肿瘤的新型疗法。然而,针对这种疗法的感染性并发症尚未有过系统的研究。

JAMA Surg:口服抗生素联合机械性肠道准备用于结直肠癌手术患者手术部位感染预防

研究认为对于接受左半结肠癌和直肠癌切除的患者,接受口服抗生素与机械性肠道准备是有效预防手术部位感染方法

Baidu
map
Baidu
map
Baidu
map